未名医药披露整改进展 停摆的重要子公司会否触发ST风险

Core Viewpoint - Unimed Pharmaceutical has faced continuous losses for three years, with intensified competition in interferon products. The cancellation of key product procurement qualifications has further diminished the company's chances of a turnaround [1][7]. Group 1: Company Performance and Challenges - Unimed Pharmaceutical's subsidiary, Tianjin Unimed, was suspended from production for one month due to non-compliance with GMP standards, leading to the cancellation of its procurement qualifications [1][2]. - The company reported a net loss of approximately 140 million yuan in 2024, with its interferon products contributing about 217 million yuan in revenue, a year-on-year decrease of 28.59% [2][7]. - The company has been in a continuous loss situation, accumulating a total loss of 484 million yuan over the past three years [7]. Group 2: Regulatory and Compliance Issues - Tianjin Unimed has signed a contract with a third-party service provider to address compliance issues and is actively cooperating with regulatory authorities to rectify deficiencies [2][3]. - The company has established a special rectification team and developed a rectification plan following the suspension of production and sales [2][3]. Group 3: Product and Market Dynamics - Unimed Pharmaceutical's main products include mouse nerve growth factor and interferon, with the latter facing fierce competition in the market [5][6]. - The company’s interferon α2b spray, which was previously awarded a procurement contract, has faced quality issues leading to the suspension of its procurement qualifications across multiple regions [5][6]. - The interferon α2b spray was priced at 33.58 yuan in the procurement process, but the execution of this contract has been jeopardized due to quality concerns [4][6].